173 related articles for article (PubMed ID: 17567477)
1. Blockade of renin-angiotensin system in antifibrotic therapy.
Yoshiji H; Kuriyama S; Fukui H
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S93-5. PubMed ID: 17567477
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 2001 Oct; 34(4 Pt 1):745-50. PubMed ID: 11584371
[TBL] [Abstract][Full Text] [Related]
4. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Yoshii J; Yanase K; Fukui H
Int J Mol Med; 2011 Jul; 28(1):81-8. PubMed ID: 21455560
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
Yoshiji H; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Tsujimoto T; Uemura M; Fukui H
Curr Med Chem; 2007; 14(26):2749-54. PubMed ID: 18045121
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
8. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
9. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
10. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
11. The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4.
Wei H; Lu H; Li D; Zhan Y; Wang Z; Huang X
Chin Med J (Engl); 2001 Jun; 114(6):583-7. PubMed ID: 11780431
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
[TBL] [Abstract][Full Text] [Related]
14. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
Yoshiji H; Kuriyama S; Noguchi R; Ikenaka Y; Yoshii J; Yanase K; Namisaki T; Kitade M; Yamazaki M; Asada K; Akahane T; Tsujimoto T; Uemura M; Fukui H
Int J Mol Med; 2006 May; 17(5):899-904. PubMed ID: 16596278
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis: a balance of ACEs?
Warner FJ; Lubel JS; McCaughan GW; Angus PW
Clin Sci (Lond); 2007 Aug; 113(3):109-18. PubMed ID: 17600527
[TBL] [Abstract][Full Text] [Related]
17. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
Fukuda D; Enomoto S; Nagai R; Sata M
Biomed Pharmacother; 2009 Dec; 63(10):754-61. PubMed ID: 19304450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]